Scinai Immunotherapeutics Ltd. 6-K Filing

From the Filing

0001213900-25-125287.txt : 20251223 0001213900-25-125287.hdr.sgml : 20251223 20251223160120 ACCESSION NUMBER: 0001213900-25-125287 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251223 FILED AS OF DATE: 20251223 DATE AS OF CHANGE: 20251223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 251600412 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0270793-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ On December 22, 2025, Scinai Immunotherapeutics Ltd (the “Company”) held an Annual Meeting of Shareholders (the “Meeting”). The total number of ordinary shares of the Company entitled to vote at the Meeting was 13,872,899,584 Ordinary Shares (each 4,000 Ordinary Shares represented by one American Depository Share (“ADS”)) and there were present, in person or by proxy, 2,498,440,000 ordinary shares, which constituted a quorum for the Meeting. The matters voted upon, and the results of the vote were as follows: Proposal 1: To approve the re-election of Mr. Mark Germain, to serve until the third annual meeting after the meeting. The shareholders approved the re-election of Mr. Mark Germain to serve until the third annual meeting after the meeting: FOR AGAINST ABSTAIN 2,381,444,000 (595,361 ADSs) 108,268,000 (27,067 ADSs) 7,896,000 (1,974 ADSs) Proposal 2: To approve an amendment to the Company’s Articles of Association (the “Articles”) to increase the number of authorized Ordinary Shares. The shareholders approved an amendment to the Company’s Articles of Association (the “Articles”) to increase the number of authorized Ordinary Shares: FOR AGAINST ABSTAIN 2,107,148,000 (526,787 ADSs) 203,692,000 (50,923 ADSs) 187,600,000 (46,900 ADSs) Proposal 3: To approve a grant of 60,000 restricted share units to Amir Reichman, the Company’s Chief Executive Officer, as a long-term incentive award reflecting his performance since the last equity award grant. The shareholders approved a grant of 60,000 restricted share units to Amir Reichman, the Company’s Chief Executive Officer, as a long-term incentive award reflecting his performance since the last equity award grant: FOR AGAINST ABSTAIN 2,095,688,000 (523,922 ADSs) 203,308,000 (50,827 ADSs) 198,612,000 (49,653 ADSs) Proposal 4: To approve a grant of options to purchase ADSs to Mr. Mark Germain, Mr. Adi Raviv, Dr. Yael Margolin, Mr. Samuel Moed and Mr. Jay Green, directors of the Company, in recognition of their continued service and contribution to the Company since the last equity award grant. The shareholders approved a grant of options to purchase ADSs to Mr. Mark Germain, Mr. Adi Raviv, Dr. Yael Margolin, Mr.